# Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization

> **NCT02479620** · PHASE2 · UNKNOWN · sponsor: **Mercator MedSystems, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Chronic Limb Ischemia

## Interventions

- **DRUG:** Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL

## Key facts

- **NCT ID:** NCT02479620
- **Lead sponsor:** Mercator MedSystems, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2019-11
- **Final completion:** 2020-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02479620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02479620, "Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02479620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*